McKesson Corporation (MCK) fair value analysis
S&P 500 · Updated 2026-10-19
MCK price how computed
Forward Fair Value verdict
Fairly valuedMCK is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $938.84
- Sector
- Healthcare
- 12-month range
- $725.17–$1,004.84
- Market cap
- $109B
- From 52-week high
- -6.6%
- Shares outstanding
- 117M
- Rank in Healthcare by discount to fair value
- #68 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
McKesson Corporation is a healthcare company that distributes pharmaceuticals, medical supplies, and healthcare information technology solutions to pharmacies, hospitals, and healthcare providers. The company operates primarily in the United States and also maintains operations in international markets including Europe, Canada, and other regions.
MCK currently ranks #68 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $109B
- P/E (trailing)
- 23x
- Revenue (TTM)
- $411B
- Net margin
- 1.1%
- EPS (TTM)
- $40.82
- Gross margin
- 3.5%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 12.2%
- Shares outstanding
- 117M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 78 · overbought
- 50-day average
- $896.43
- 200-day average
- $853.97
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $3.40 per share (4 payments)
- Yield on last price
- 0.36%
- Consecutive years of increases
- 18
- Last ex-dividend date
- 2026-09-01
- Last payment date
- 2026-10-01
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+5.2%)
2026-03 ▲ beat (+1.0%)
2025-12 ▲ beat (+0.8%)
2025-09 ▲ beat (+10.5%)
2025-06 ▲ beat (+1.3%)
2025-03 ▲ beat (+3.0%)
2024-12 ▲ beat (+0.5%)
2024-09 ▲ beat (+2.9%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 13 buy · 4 hold · 0 sell (17 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $1000
- Target vs last price
- +6.5%
What our data shows for MCK
- Our model validated 17 trailing price-to-earnings windows for MCK, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $725.17–$1,004.84.
- The 14-day relative strength index sits at an overbought 78.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for MCK
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MCK news
TickrTrends' derived news-sentiment signal for MCK is currently leaning positive, computed from recent coverage.
- Is Trending Stock McKesson Corporation (MCK) a Buy Now? (zacks.com, 2026-10-21)
TickrTrends take: McKesson Corporation operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends analysis. For investors focused on valuation metrics, a fairly valued rating suggests the current price already reflects the company's fundamental worth, meaning significant upside from valuation expansion alone may be limited without operational improvements or sector tailwinds. Valuation-focused readers should monitor whether MCK demonstrates earnings growth or margin expansion that could justify multiple expansion beyond its current fairly valued assessment. - McKesson: Re-Rated Again Amidst Increased M&A Efforts (NYSE:MCK) (seekingalpha.com, 2026-10-13)
TickrTrends take: McKesson's increased merger and acquisition activity represents a strategic shift that could impact future earnings power and cash flow generation, factors central to any valuation reassessment. As the Healthcare sector often experiences consolidation cycles, investors focused on valuation should monitor whether MCK's M&A efforts result in accretive deals that justify potential premium multiples or whether integration costs weigh on near-term profitability. Given TickrTrends' current fairly valued assessment, the outcome of these acquisition efforts will be critical in determining whether the stock warrants a repricing upward or downward in coming quarters. - McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified? (insidermonkey.com, 2026-10-09)
TickrTrends take: McKesson's acquisition of Option Care Health for 5 billion dollars represents a significant expansion of its healthcare services footprint, which TickrTrends currently values as fairly valued. For valuation-focused readers, the key metric to monitor is how this acquisition impacts McKesson's profitability metrics and return on invested capital relative to the purchase price, since large healthcare sector acquisitions can either enhance or dilute shareholder value depending on integration success. The integration's effect on operating margins and free cash flow generation will be essential indicators of whether the fairly valued assessment holds or requires adjustment.
More MCK news
- Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now? (zacks.com, 2026-10-07)
What people are saying
Follow the MCK conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for MCK have shifted this week, with the Relative Strength Index moving from a neutral zone into overbought territory. The stock maintains a fairly valued assessment based on current valuation metrics. This technical shift suggests increased upward momentum in the healthcare sector stock over the past week.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — MCK's sector discount rank declined from 73 to 81 this week, indicating the stock has moved to a less attractive valuation position relative to other healthcare sector companies. The stock remains fairly valued according to current assessment, though its relative valuation standing within the sector has weakened over the past week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MCK stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), MCK is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is MCK's TickrTrends verdict?
MCK's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does MCK compare to other Healthcare stocks?
MCK ranks #68 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is MCK overbought or oversold?
MCK's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.
Does MCK pay a dividend?
Yes. MCK paid $3.40 per share over the last twelve months (4 payments), a 0.36% yield on TickrTrends' last price, and has raised the annual total for 18 consecutive years. The last ex-dividend date was 2026-09-01.
When does MCK report earnings next?
MCK's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does MCK usually beat earnings estimates?
Over its last 8 reported quarters MCK beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MCK?
Of 17 analysts covering MCK, 13 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $1000 (+6.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
MCK vs ABCL · MCK vs ABSI · MCK vs BIIB · MCK vs BMY · MCK vs BVS